Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEHAB II penile rehabilitation after nerve-sparing radical prostatectomy
NL-OMON59838Phase 4Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sildenafil in erectile dysfunction (ED) and prostate cancer (PCa) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Rate of adequate spontaneous unassisted erections at 24 months. Started Jan 2024; status: active, not recruiting.
02
Drugs
sildenafil
03
Conditions
erectile dysfunction (ED)prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59838.